Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02896712 · ClinicalTrials.gov registry record · Phase 2
Developing Adaptive Interventions for Cocaine Cessation and Relapse Prevention
A Phase 2 study of Cocaine-Related Disorders, sponsored by The University of Texas Health Science Center, Houston.
- Completed
- Registry status
- Phase 2
- Development phase
- 118
- Enrollment target
- 1
- Study location
NCT02896712 is a Phase 2 study of Cocaine-Related Disorders that has completed, run by The University of Texas Health Science Center, Houston. The registered enrollment target is 118 participants, above the 57-participant average among 15 other Cocaine-Related Disorders trials with a reported enrollment target (107% higher). The trial reports 1 study location across 1 state.
The verdict
NCT02896712, a Phase 2 study of Cocaine-Related Disorders, has completed, sponsored by The University of Texas Health Science Center, Houston.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 118 participants
- Enrollment target
- 1
- Study location
Study Summary
First, the investigators will determine whether Acceptance and Commitment Therapy in combination with Contingency Management increases initial treatment response rates. Second, for patients who do not respond to initial treatment, the investigators will examine whether dopamine-targeted pharmacotherapy is an effective augmentation strategy. Third, for patients who respond to initial treatment, the investigators will assess the relative benefit of continued treatment with Acceptance and Commitment Therapy in combination with Contingency Management, as compared to Drug Counseling in combination with Contingency Management, to prevent relapse.
Conditions Studied
Interventions
- DRUG Placebo
- BEHAVIORAL Acceptance and Commitment Therapy (ACT)
- DRUG Modafinil
- BEHAVIORAL Contingency Management (CM)
- BEHAVIORAL Drug Counseling (DC)
Study Locations (1)
Texas
- UTHealth Center for Neurobehavioral Research on Addiction - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 118 participants |
| Start Date | 2016-11-18 |
| Est. Completion | 2021-09-13 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02896712
The ClinicalTrials.gov registry entry for NCT02896712 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 118 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 57-participant average among 15 other Cocaine-Related Disorders trials with a reported enrollment target (107% higher). The listed sponsor is The University of Texas Health Science Center, Houston, which has 732 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Cocaine-Related Disorders appearing as the primary indexed condition, and to 5 interventions - of which Placebo is the first listed.
NCT02896712 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT02896712 about?
NCT02896712 is a clinical study titled "Developing Adaptive Interventions for Cocaine Cessation and Relapse Prevention". First, the investigators will determine whether Acceptance and Commitment Therapy in combination with Contingency Management increases initial treatment response rates. Second, for patients who do not respond to initial treatment, the investigators will examine whether dopamine-targeted pharmacothe...
What is the current status of trial NCT02896712?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 118 participants. The study started on 2016-11-18. Estimated completion is 2021-09-13.
What conditions does trial NCT02896712 study?
This clinical trial studies the following conditions: Cocaine-Related Disorders.
What interventions are being tested in trial NCT02896712?
The interventions under investigation include: Placebo (DRUG), Acceptance and Commitment Therapy (ACT) (BEHAVIORAL), Modafinil (DRUG), Contingency Management (CM) (BEHAVIORAL), Drug Counseling (DC) (BEHAVIORAL).
Who is sponsoring clinical trial NCT02896712?
This trial is sponsored by The University of Texas Health Science Center, Houston, which has 732 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02896712 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cocaine-Related Disorders
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Atomoxetine for Treating Cocaine Abuse in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
COMPLETED · Phase 2
-
Pharmacological Modulation of Cocaine Effects - 1
COMPLETED · Phase 2
-
Gepirone vs Placebo in Treatment of Cocaine Dependence - 3
COMPLETED · Phase 2
-
Risperidone Treatment in Dually-Diagnosed Individuals - 2
COMPLETED · Phase 2
-
Combination of Disulfiram Plus Naltrexone to Treat Both Cocaine- and Alcohol-dependent Individuals - 1
COMPLETED · Phase 2
-
Evaluation of Benztropine for Cocaine Craving - 2
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.